Eskayef Pharma’s remdesivir is a headache for Indian drugmakers
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
FRIDAY, MAY 20, 2022
FRIDAY, MAY 20, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Eskayef Pharma’s remdesivir is a headache for Indian drugmakers

Coronavirus chronicle

TBS Report
09 June, 2020, 11:30 am
Last modified: 09 June, 2020, 11:40 am

Related News

  • Indian police charge 30 anti-Vedanta protesters over deadly 2018 demonstration
  • India's power grid creaks under hybrid work model, heatwave
  • JPMorgan downgrades India's IT sector as Covid boom fades
  • India retains top spot as fastest-growing economy: UN
  • Sundarban tigers travelling to West Bengal in search of mates

Eskayef Pharma’s remdesivir is a headache for Indian drugmakers

Remdesivir is one alternative on the table that has been approved for treating Covid-19 in India but is yet to be released

TBS Report
09 June, 2020, 11:30 am
Last modified: 09 June, 2020, 11:40 am
Photo: Collected.
Photo: Collected.

India's Maharashtra government is going to import Gilead's antiviral drug Remdesivir from Bangladeshi drug maker Eskayef Pharmaceuticals and it has taken the Indian pharmaceutical industry by surprise.

Yet analysts and legal experts have found out that if the drug is not for commercial use it is completely safe to import it.

On June 6, Maharashtra Health Minister Rajesh Tope said the state will buy Rs 12,000 per vial for 10,000 doses of remdesivir from Dhaka-based Eskayef Pharma, reports Moneycontrol.

Gilead told Moneycontrol it has not given a license to manufacture remdesivir to Eskayef Pharmaceuticals or any other business in Bangladesh.

"Gilead cannot comment on or verify the authenticity or effectiveness of this product as it is not manufactured by Gilead or one of our licensed partners," it said.

The announcement of Maharashtra came even as three Indian companies-Cipla, Hetero and Jubilant Life Sciences-are awaiting approvals from the Indian drug regulator for marketing authorisation. The three firms hold Gilead licenses to manufacture and sell the medication in 127 low- and middle-income (LMICS) countries.

Maharastra reported 82,968 cases, and 2,969 deaths due to Covid-19, India's highest. Remdesivir is one alternative on the table that has been approved for treating Covid-19 in India but is yet to be released. This prompted the state government to go for Eskayef's Remdesivir.

"We should not have any concern (on any IP infringement). DCGI is conversant with the IP provisions, and has acted promptly in granting the import (to Bangladesh company)" said Dr Gopakumar Nair, Gopakumar Nair Associates, a Mumbai-based consultant for Intellectual Property (IP) related matters.

Nair said Section 107A of the Patents Act, 1970, provides for the importation of the drug if the company is duly authorised to produce and sell or distribute the product under the law. Nair also quoted Section 100 of the Patent Act, which specifies that a proprietary invention should be used for  'for purposes of Government'.

Nair is a consultant with Beximco Pharma, another drug-maker from Bangladesh who produces remdesivir.

Racing ahead

Two Bangladesh companies - Eskayef Pharmaceuticals and Beximco Pharma - have started making and distributing remdesivir without Gilead's approvals. These companies have been quick to take advantage of international trade rules that allow nations defined by the United Nations as least-developed countries to ignore patents and produce affordable drugs. Bangladesh comes under least-developed country.

They are also exporting remdesivir to other countries, putting them directly in race with Indian drugmakers.

Another analyst told that remdesivir made in Bangladesh is not inferior and made in USFDA compliant facilities.

"Many Indian technical and legal consultants have helped Bangladesh companies. Bangladesh has aspirations to become powerhouse of generic drug manufacturing. It has decent technical expertise and has built many USFDA compliant facilities. Given its status as least-developed country, it can easily copy patented drugs. Covid-19 gave them perfect opportunity to put those skills to use," said a partner at one of the big four consulting firms on condition of anonymity.

Wait for Indian-made remdesivir continues

An executive of a drug maker who has a license from Gilead for remdesivir and whose application for marketing authorisation in pending with Drug Controller General of India (DCGI) told Moneycontrol that the regulator has sought data on animal toxicology studies.

"We are in the process of submitting the data," the executive said. The Indian regulator had given clinical trial waiver for the drug.

The executive declined to comment on the Eskayef drug, but said his company would price the drug at an affordable rate.

As per the agreement with Gilead India, companies are free to price the drug. Gilead is yet to fix the price for US market.

The Institute for Clinical and Economic Review (ICER), the Boston-based independent nonprofit organisation, which has done cost benefit modelling has estimated the price of the drug at $4460 (Rs 3,36,779) for a full course of treatment in US .

In terms of pricing, Bangladesh companies are selling Remdesivir in local market at 7000 takas per vial, which puts the five-day treatment cost at 35,000 takas (Rs 31,000), that's one-tenth of the price.

Bangladesh / Top News / World+Biz

remdesivir / India / Eskayef Pharma / Beximco Pharma

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Students suffer over costlier food at public university canteens
    Students suffer over costlier food at public university canteens
  • A worker displays grains of wheat at a mill in Beirut, Lebanon, March 1, 2022. REUTERS/Mohamed Azakir/File Photo
    Russia can offer 25 mln tonnes of grain for export starting on 1 Aug: UN envoy
  • A model of the natural gas pipeline is seen in front of displayed Finnish and Russian flag colours in this illustration taken April 26, 2022. REUTERS/Dado Ruvic/Illustration
    Russian gas flows to Finland to stop on Saturday, says Gasum

MOST VIEWED

  • Ryu Yong Chol, an official at North Korea's state emergency epidemic prevention headquarters, speaks during a daily coronavirus program on state-run television KRT, in this still image obtained from KRT footage released on May 20, 2022. REUTERS TV/KRT via REUTERS
    North Korea's Dr Fauci? Health official emerges as face of Covid campaign
  • Workers in protective suit spray disinfectant at a community, during the lockdown to curb the spread of the coronavirus disease (COVID-19) in Shanghai, China, April 5, 2022. REUTERS/Aly Song
    Shanghai detects new infections after five days of 'zero Covid'
  • Volunteers carry out temperature screening during an anti-virus campaign in Pyongyang, North Korea in this image released by North Korea's Korean Central News Agency (KCNA) on March 4, 2020. KCNA via REUTERS/File Photo
    North Korea hails 'good results' on Covid as fever cases pass 2 million
  • Medical staff members check the temperature of people as they enter at Capital Airport, following an outbreak of Covid-19, in Beijing, China, 5 November, 2020. Photo: Reuters
    China relaxes some Covid test rules for US, other travellers
  • Representational image.
    China Junshi's potential Covid drug shows promise in small trial
  • A woman wearing protective mask walks at a sidewalk near business district in Jakarta, Indonesia March 2, 2020. REUTERS/Willy Kurniawan/Files
    Indonesia to drop outdoor mask mandate as Covid-19 infections drop

Related News

  • Indian police charge 30 anti-Vedanta protesters over deadly 2018 demonstration
  • India's power grid creaks under hybrid work model, heatwave
  • JPMorgan downgrades India's IT sector as Covid boom fades
  • India retains top spot as fastest-growing economy: UN
  • Sundarban tigers travelling to West Bengal in search of mates

Features

Mohammad (Mejbah) Mejbahuddin, Former Senior Secretary, Economic Relations Division (ERD), Ministry of Finance, Government of Bangladesh. TBS Sketch

‘No project is being delayed too long at the moment’

1h | Panorama
Dr Shamsul Hoque, Professor, Civil Engineering, BUET. TBS Sketch

‘Planning commission only in the name, there are no planners’ 

1h | Panorama
Masrur Reaz. TBS Sketch

‘To ensure accountability, contract financing should be based on ‘performance based payments’

2h | Panorama
Professor Mustafizur Rahman. Illustration: TBS

Project delays and escalating costs are driven by frequent revisions and lack of good governance

5h | Panorama

More Videos from TBS

Ways to retain body fragrance

Ways to retain body fragrance

3h | Videos
Gazipur restaurant that serves 150 food items

Gazipur restaurant that serves 150 food items

6h | Videos
How to prepare for a job

How to prepare for a job

7h | Videos
Putin's strategies to face Nato

Putin's strategies to face Nato

19h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

3
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

4
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

5
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

6
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab